Tumor Markers Overview

Tumor markers refer to a type of biologically active substances produced by tumor cells or body reactions during the occurrence and development of tumors, which can be detected in blood, body fluids or tissues. They are mainly used to assist in the early screening, diagnosis, efficacy evaluation and recurrence monitoring of cancer. Common markers include proteins (such as AFP, CEA), hormones (such as HCG), gene mutations (such as BRCA), etc. Although its specificity is limited and requires comprehensive judgment combined with imaging or pathological examinations, it is still an important tool in modern cancer diagnosis and treatment. The following sections will focus on definitions, clinical applications, limitations, and future directions.

Definition and classification of tumor markers

Tumor markers can be divided into three categories based on their source:cell surface antigen(such as CA125),secreted protein(such as PSA) andabnormal genetic products(such as EGFR mutations). For example, AFP (alpha-fetoprotein) is commonly used in liver cancer screening, while CA19-9 is associated with pancreatic cancer. Levels of these markers are low in healthy people but may be significantly elevated in cancer patients. It should be noted that some benign diseases (such as inflammation) may also cause false positives, so the analysis needs to be combined with clinical manifestations.

Clinical application and value

The core value of tumor markers is reflected indynamic monitoring. For example, CEA (carcinoembryonic antigen) can indicate the risk of recurrence during regular testing after colorectal cancer surgery. In addition, some markers such as HER2/neu can guide targeted therapy (such as the use of Herceptin). However, a single marker is not sensitive enough, and combined detection is often required. Taking lung cancer as an example, NSE (neuron-specific enolase) is associated with small cell lung cancer, while CYFRA21-1 is more suitable for non-small cell lung cancer.

Limitations and precautions

tumor markerFalse positive/negative rateis the main limitation. Smoking may slightly increase CEA levels, and some patients with early-stage tumors may have normal markers. In addition, the results of different detection methods (such as ELISA, chemiluminescence method) may vary. Doctors often recommend a combination of imaging or biopsy for people at higher risk (e.g., family history) to avoid overreliance on marker testing.

Future development and summary

With advances in liquid biopsy technology (such as ctDNA), tumor markers are on the riseMulti-omics integrationdirection development. For example, exosome-based markers may improve early detection rates. Currently, detection kits (such as the Elecsys series) developed by Roche, Abbott and other companies have been widely used. However, it must be clear that markers are only auxiliary tools, and the final diagnosis still requires comprehensive evaluation.

Quote source:
1. "Clinical Application Guidelines for Tumor Markers in China" (Oncology Branch of the Chinese Medical Association, 2022)
2. American Cancer Society (ACS) official website: Interpretation of tumor markers
3. Manufacturer: Roche Diagnostics (product name: Elecsys AFP), Abbott (product name: Architect PSA)